HLB Pep Co., Ltd.

Company Profile

Sector

Basic Materials

Industry

Chemicals

Employees

N/A

Website

hlbpep.co.kr

Country

South Korea

Exchange

KOSDAQ

Founded 2000Gwangju-si, South Korea

HLB Pep Co., Ltd., a bio-venture company provides the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and globally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services.

The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy.

Its portfolio also includes AGM-380 indicated for the treatment of viral infection, and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria.

Additionally, it is involved in the development of AGM-212 indicated for the treatment of Type 2 Diabetes. Its portfolio also includes AGM-217 indicated for the treatment of Type 2 diabetes and obesity, and AGM-260 indicated for the treatment of Ulcerative colitis. Founded in 2000 and headquartered in Gwangju-si, South Korea, the company was formerly known as Anygen Co., Ltd. before rebranding in April 2025.

Key Stats

52-Week Range

₩3510.00₩9990.00

Beta0.15

Trailing P/EN/A

Forward P/EN/A

Trailing EPSN/A

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.